BCR-ABL1-negative myeloproliferative Neoplasien (MPN)

BCR-ABL1-negative myeloproliferative Neoplasien (MPN) sind eine sehr heterogene Gruppe klonaler myeloischer Erkrankungen, die durch gesteigerte Proliferation und begleitende Inflammation gekennzeichnet sind. Dieser Artikel gibt einen Überblick zu Therapiestandards der Hauptentitäten Polycythaemia vera, essentielle Thrombozythämie sowie Myelofibrose.

Publication History

Article published online:
11 May 2020

• Literatur

• 1 Zoi K, Cross NC. Genomics of Myeloproliferative Neoplasms. J Clin Oncol 2017; 35: 947-954
• 2 Arber DA, Orazi A, Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-2405
• 3 Landolfi R, Marchioli R, Kutti J. et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114-124
• 4 Gisslinger HKC, Georgiev P, Krochmalczyk D. et al. Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT. Blood 2018; 132 (Suppl. 01) 579
• 5 Verstovsek S, Mesa RA, Gotlib J. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807
• 6 Harrison C, Kiladjian JJ, Al-Ali HK. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787-798
• 7 Verstovsek S, Mesa RA, Gotlib J. et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 2017; 10: 55
• 8 Kvasnicka HM, Thiele J, Bueso-Ramos CE. et al. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. J Hematol Oncol 2018; 11: 42
• 9 Pardanani A, Harrison C, Cortes JE. et al. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol 2015; 1: 643-651
• 10 Harrison CN, Schaap N, Vannucchi AM. et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 2017; 4: e317-e324
• 11 Guglielmelli P, Lasho TL, Rotunno G. et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 2014; 28: 1804-1810
• 12 Finazzi G, Vannucchi AM, Barbui T. Prefibrotic myelofibrosis: treatment algorithm 2018. Blood Cancer J 2018; 8: 104